TP53 and lung adenocarcinoma: Simvastatin inhibits proliferation and osteolytic bone metastases of lung adenocarcinoma cells in vitro and in vivo. Its mechanism might be linked with regulating the CD44, P53, and MMP family and inactivating the MAPK/ERK signaling pathway.